Effect of Selenium Supplementation on Mild Graves’ Ophthalmopathy at a Tertiary Hospital – a Six-Month, Open-Labelled, Assessor-Masked, Randomized Controlled Trial

Joy Mangubat Flores, Niña Angelica G. Sioson, Armida L. Suller-Pansacola, Jean D. Uy-Ho

Apr 2025 DOI 10.35460/2546-1621.2025-0002     Access   

Abstract

Objective: This study aimed to determine if selenium supplementation for a period of six months can decrease signs and prevent worsening of mild Graves’ ophthalmopathy among Filipino patients.

Methods: We conducted an open-label, assessor-masked, randomized controlled trial involving adult patients diagnosed with mild Graves’ ophthalmopathy. Participants were divided into two groups: one group received standard care (eye drops) alone (control group), while the other group received an additional 200 mcg/day oral selenium supplementation alongside standard care. Inclusion criteria encompassed adult patients with Graves’ hyperthyroidism presenting at least one sign of mild ophthalmopathy and a disease duration of less than 18 months. Statistical analyses were performed using independent sample t-test, Mann-Whitney U test and Fisher’s Exact/Chi-square test to compare means, ranks and frequencies between the two intervention groups. Paired sample t-test, Wilcoxon signed rank test and McNemar test were employed to assess changes from baseline to the third and sixth month observations.

Results: A significant difference in clinical activity score (CAS) was observed between the selenium supplementation group and the control group. Initially, 14 eyes (33.33%) in the selenium group exhibited a CAS score of 0, which increased to 27 eyes (64.29%) at the third month of treatment and slightly decreased to 26 eyes (61.9%) at the sixth month. Conversely, the control group had 11 eyes with a CAS score of 0 at baseline, which increased to 16 eyes (38.1%) at three months and decreased to 14 eyes (33.33%) at the sixth month. The improvement in CAS was significantly associated with reductions in caruncle and plica swelling (p = 0.040). Further analysis revealed a statistically significant difference in CAS between the treatment and control groups (p = 0.017) at the sixth month mark.

Conclusion: Selenium supplementation provided significant benefit in reducing the signs and preventing deterioration of mild Graves’ ophthalmopathy, as indicated by improved CAS scores. Future research exploring baseline and end of treatment selenium concentrations in the Philippines is recommended to further substantiate these findings.

  1. Gontarz-Nowak K, Szychlińska M, Matuszewski W, Stefanowicz-Rutkowska M, Bandurska-Stankiewicz E. Current knowledge on Graves’ orbitopathy. J Clin Med [Internet]. 2020;10(1):16. Available from: http://dx.doi.org/10.3390/jcm10010016  

  2. Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y. Graves’ ophthalmopathy: epidemiology and natural history. Intern Med [Internet]. 2014;53(5):353–60. Available from: http://dx.doi.org/10.2169/internalmedicine.53.1518 

  3. Lat AM, Jauculan MC, Sanchez CA, Jimeno C, Sison-Peña CM, Pe-Yan MR, et al. Risk factors associated with the activity and severity of Graves’ ophthalmopathy among patients at the university of the Philippines manila-Philippine General Hospital. J ASEAN Fed Endocr Soc [Internet]. 2017;32(2):151–7. Available from: http://dx.doi.org/10.15605/jafes.032.02.09 

  4. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J [Internet]. 2016;5(1):9–26. Available from: http://dx.doi.org/10.1159/000443828 

  5. Chaudhry IA. Thyroid associated orbitopathy: Understanding pathophysiology. Saudi J Ophthalmol [Internet]. 2011;25(1):1–2. Available from: http://dx.doi.org/10.1016/j.sjopt.2010.11.001

  6. Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy. Front Endocrinol (Lausanne) [Internet]. 2020;11:615993. Available from: http://dx.doi.org/10.3389/fendo.2020.615993 

  7. Palisoc E, Morabe E, Pagkatipunan PM. Prevalence of Graves’ ophthalmopathy among patients with thyroid disease. Philipp J Ophthalmol. 2010;35(1):32–5.

  8. Drui D, Du Pasquier Fediaevski L, Vignal Clermont C, Daumerie C. Graves’ orbitopathy: Diagnosis and treatment. Ann Endocrinol (Paris) [Internet]. 2018;79(6):656–64. Available from: http://dx.doi.org/10.1016/j.ando.2018.08.005 

  9. Bednarczuk T, Schomburg L. Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy. Hormones (Athens) [Internet]. 2020;19(1):31–9. Available from: http://dx.doi.org/10.1007/s42000-019-00133-5 

  10. Bednarczuk T, Schomburg L. Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy. Hormones (Athens). 2020;19(1):31–9.

  11. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med [Internet]. 2011;364(20):1920–31. Available from: http://dx.doi.org/10.1056/NEJMoa1012985 

  12. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst [Internet]. 2003;95(19):1477–81. Available from: http://dx.doi.org/10.1093/jnci/djg061 

  13. Kahaly GJ, Riedl M, König J, Diana T, Schomburg L. Double-blind, placebo-controlled, randomized trial of selenium in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2017;102(11):4333–41.

  14. Wang C, Qiao J, Liu S, Piao S, Zhou Y, Hu Y, et al. Selenium in the treatment of mild-to-moderate Graves’ orbitopathy: a 5-year prospective controlled cohort study. Endocrine [Internet]. 2024;84(3):1072–80. Available from: http://dx.doi.org/10.1007/s12020-023-03672-5 

  15. Wang Y, Patel A, Douglas RS. Thyroid eye disease: How a novel therapy may change the treatment paradigm. Ther Clin Risk Manag [Internet]. 2019;15:1305–18. Available from: http://dx.doi.org/10.2147/TCRM.S193018 

  16. Lanzolla G, Marinò M, Marcocci C. Selenium in the treatment of Graves’ hyperthyroidism and eye disease. Front Endocrinol (Lausanne) [Internet]. 2020;11:608428. Available from: http://dx.doi.org/10.3389/fendo.2020.608428 

Articles related to the one you are viewing

There are currently no results to show, please try again later

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.